Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Randy Scott

Incyte Corporation

Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage biopharmaceutical company focused on in-licensing, developing and commercializing oncology drug candidates in China, US, and the rest of the world.

Xynomic Pharmaceuticals Holdings, Inc.

Incyte Medical

Cholangiocarcinoma Europe

MPN Quality Initiatives

Vitiligo Europe

DLBCL Europe

FGFRScience

MPN Connect

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.

We are committed to the relentless pursuit of science that can improve the lives of patients.

Our unique expertise in medicinal chemistry and biology has enabled us to create a diversified portfolio of marketed products and clinical candidates, the majority of which were discovered by Incyte scientists. We are advancing a growing pipeline of medicines across Oncology and Inflammation & AutoImmunity.

Headquartered in Wilmington, Delaware, Incyte has more than 1,700 employees and operations in North America, Europe and Asia.
We are proud to have been recently recognized by Forbes as one of the World’s Most Innovative Companies. Additionally, Incyte has consecutively been named a Top Employer by Science Magazine, placing #2 on the 2020 list.

For more information about Incyte, please visit our corporate website at www.incyte.com and follow us on Twitter: www.twitter.com/incyte. See our Community Guidelines: http://bit.ly/2sV0H5W.


GeneEd

Iconix Biosciences

Agenus

Incyte

Join us at the 42nd Annual J.P. Morgan Healthcare Conference today, where we'll be discussing our pipeline and commitment to pushing the boundaries of scientific innovation. #JPM24 #News https://bit.ly/3tJny43

This weekend, Incyte was involved in the collaboration and discussion of research from the #oncology and #hematology space at the American Society of Hematology Annual Meeting. #SolveOn #ASH23

New research on myeloproliferative neoplasms (MPNs) was shared today at #ASH23. Hear from Patrick Mayes, Vice President of Biotherapeutic Research at Incyte, on what this may mean for the MPN community.

Peter Langmuir, Group Vice President, Oncology Targeted Therapeutics at Incyte, shares thoughts on the AGAVE-201 trial for patients with refractory chronic graft-versus-host disease (GVHD). #ASH23

Metric
Company Name	Incyte Corporation	Fairmount Funds	Xynomic Pharmaceuticals Holdings, Inc.
Symbol	INCY
MSH ID	COM:INCYTE	COM:FAIRMOUNTFUNDS	COM:XYNOMICPHARMA
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology	Investment Management	Pharmaceuticals
Country	US	US	US
Stage			Series B
Employee Count	2.52K
Website	incyte.com	fairmountfunds.com	xynomicpharma.com
LinkedIn	incyte	fairmount-funds-management-llc
Founders

Metric
Market Cap	13.66B
Enterprise Value
Monthly Web Traffic	70.55K	88	1.52K
Web Traffic Growth	-0.09	-0.70	4.19
Valuation
Raised Capital

Metric
Revenue	3.70B
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.44B
EBITDA	904.74M
Operating Income	620.52M
Net Income	597.60M
EPS	2.67
Diluted EPS	2.65
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.93
Operating Profit Margin	0.19
EBITDA Margin	0.24
Net Profit Margin	0.20
Return on Equity	0.15
Return on Assets	0.10
Return on Capital Employed	0.12

COM:INCYTE

Incyte Corporation

Last Close

70.39

22/11 21:00

Market Cap

13.66B

Beta: -

Volume Today

1.52M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	30.70
P/B Ratio	2.65
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	4.09
EV Multiple	64.64

Metric
Days Sales Outstanding	66.47
Days Payables Outstanding	1.82K
Days Inventory Outstanding	137.40
Operating Cycle	207.33
Cash Conversion Cycle	8.90
Asset Turnover	0.83

Metric
Operating Cash Flow	496.49M
Free Cash Flow	449.00M
Cash Flow to Debt	25.17
Operating Cash Flow/Sales	0.22
Free Cash Flow Yield	0.04

Metric
Cash & Equivalents	3.21B
Accounts Receivable	-98.68M
Inventory	62.97M
Goodwill	155.59M
Debt to Capitalization	0.01
Debt to Assets	0.01
Current Ratio	3.80
Quick Ratio	3.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.06
R&D to Revenue	0.47
SG&A to Revenue	0.32